Jonathan Trent, MD, PhD

Sylvester Comprehensive Cancer Center, University of Miami Health System
Miami, Florida, United States

Disclosure information not submitted.

Presentation(s):

• Paper 10 - THE NOVEL KIT INHIBITOR IDRX-42 SHOWS PROMISING ACTIVITY IN 2ND AND LATER-LINE GASTROINTESTINAL STROMAL TUMORS: RESULTS FROM A PHASE 1 STUDY (STRATEGIST 1)

  Thursday, November 14, 2024
  10:30 AM – 11:30 AM PST

• Paper 66 - CHARACTERIZING THE GENOMIC LANDSCAPE OF MALIGNANT PERIVASCULAR EPITHELIOID CELL FAMILY OF TUMORS IN A REAL-WORLD PATIENT POPULATION USING THE FOUNDATION MEDICINE GENOMIC DATABASE

  Friday, November 15, 2024
  4:00 PM – 5:00 PM PST

• Paper 79 - PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN LOCALLY ADVANCED OR METASTATIC IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA UNTREATED OR PREVIOUSLY TREATED WITH 1 SYSTEMIC TREATMENT REGIMEN (CHONQUER)

  Saturday, November 16, 2024
  9:00 AM – 10:00 AM PST

• Paper 88 - IMMUNE CORRELATES OF RESPONSE TO COMBINATION AXITINIB PLUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS INCLUDING ALVEOLAR SOFT PART SARCOMA

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 111 - UNEVEN BATTLE: EXPLORING RACIAL, GENDER AND ETHNIC DISPARITIES IN SOFT TISSUE SARCOMA MORTALITY TRENDS IN THE UNITED STATES OF AMERICA

  Saturday, November 16, 2024
  4:30 PM – 5:30 PM PST